Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II studyResearch in context

Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II studyResearch in context

Summary: Background: High-grade neuroendocrine neoplasms (NENs) have limited treatment options following first-line platinum-based chemotherapy, often resulting in poor clinical outcomes. Dual immune checkpoint blockade targeting CTLA-4 and PD-1 offers a synergistic approach by enhancing T-cell act...

Full description

Saved in:
Bibliographic Details
Main Authors: Panpan Zhang, Kai Chen, Jianwei Yang, Lijie Song, Fei Zheng, Ruixuan Luo, Yebo He, Feng Li, Di Yang, Nan Cao, Xiaolu Tao, Lin Shen, Ming Lu
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:EClinicalMedicine
Subjects:
Neuroendocrine neoplasms
Immune checkpoint inhibitors
HBM4003
Toripalimab
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537025001816
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2589537025001816

Similar Items